BriaCell Therapeutics Operating Income

BriaCell Therapeutics (BCTX) currently reports a operating income of $500K as of April 2026. That compares with $-24M in the prior-year period — up 102.1% year over year. Use the charts on this page to explore BriaCell Therapeutics's operating income history and peer comparisons.

BriaCell Therapeutics's operating income increased from $-24M to $500K — a 102.1% year-over-year increase (period ending April 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BriaCell Therapeutics reported $500K in operating income as of April 2026. That compares with $-24M in the prior-year period — up 102.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $500K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BriaCell Therapeutics, and consider following BCTX for alerts when major investors trade the stock.

BriaCell Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $500K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCTX with unrelated industries.